All In Biotech

Drug Trial Radar · NCT02108964

A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies

Last checked: Nov 20, 2026Latest source record: Dec 11, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

225

Actual

Start

Jun 6, 2014

Primary completion

Mar 22, 2018

Study completion Aug 15, 2023

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Apr 9, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase I/II, multi-center, open-label study, composed with a Phase I part (dose-escalation phase) followed by a Phase II part (expansion phase). The dose escalation phase was designed to determine as primary objective the maximum tolerated dose (MTD) or recommended Phase II dose (RP2D) of EGF816 monotherapy in adult subjects with locally advanced (stage IIIB) or metastatic (stage IV) NSCLC harboring specific EGFR mutations. Patients may have or not have received prior lines of antineoplastic therapy. An adaptive Bayesian Logistic Regression Model (BLRM) employing the escalation with overdose control (EWOC) principle will be used during the dose escalation part for dose level selection and MTD recommendation. The primary objective of the Phase II part is to estimate antitumor activity of EGF816 as measured by overall response rate (ORR) determined by Blinded Independent Review Committee (BIRC) assessment in accordance to RECIST 1.1.

Conditions

  • Advanced Non-small Cell Lung Cancer

Interventions

  • EGF816Drug

    EGF816 will be dosed once daily. On the first day of each treatment cycle, the patient receives an adequate drug supply for self-administration at home. The investigator will instruct the patient to take EGF816 exactly as prescribed.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Dose Limiting Toxicities (DLTs) (Phase I Part)Time frame: First 28 days of dosing
  2. Overall Response Rate (ORR) by Blinded Independent Review Committee (BIRC) (Phase II Part)Time frame: From baseline up to 64 weeks

Locations

14 sites in 9 countries. Site status is shown where the registry gives one.

  • Massachusetts General Hospital Mass General

    Boston, Massachusetts

  • Memorial Sloan Kettering Oncology Department

    New York, New York

  • Novartis Investigative Site

    Toronto, Ontario, Canada

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Cologne, Germany

  • Novartis Investigative Site

    Nagoya, Aichi-ken, Japan

  • Novartis Investigative Site

    Fukuoka, Fukuoka, Japan

  • Novartis Investigative Site

    Zoetermeer, Netherlands

  • Novartis Investigative Site

    Singapore, Singapore

  • Novartis Investigative Site

    Seoul, South Korea

  • Novartis Investigative Site

    Seoul, South Korea

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Barcelona, Catalonia, Spain

  • Novartis Investigative Site

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.